Cargando…

T-lymphoid progenitor-based immunotherapies: clinical perspectives for one and all

Detalles Bibliográficos
Autores principales:	Gaudeaux, P., Moirangthem, R. D., Paillet, J., Martin-Corredera, M., Sadek, H., Rault, P., Joshi, A., Zuber, J., Soheili, T. S., Negre, O., André, I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709039/ https://www.ncbi.nlm.nih.gov/pubmed/36180781 http://dx.doi.org/10.1038/s41423-022-00927-5

Ejemplares similares

Author Correction to: T-lymphoid progenitor-based immunotherapies: clinical perspectives for one and all
por: Gaudeaux, P., et al.
Publicado: (2022)

T-Cell Progenitors As A New Immunotherapy to Bypass Hurdles of Allogeneic Hematopoietic Stem Cell Transplantation
por: Gaudeaux, Pierre, et al.
Publicado: (2022)

P1257: SMART101 DONOR T-LYMPHOID PROGENITORS TO ACCELERATE IMMUNE RECONSTITUTION POST-HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: SI101-02 PHASE I/II
por: Ciceri, Fabio, et al.
Publicado: (2023)

P1403: SI101-01 PHASE I/II STUDY EVALUATING SAFETY AND EFFICACY OF ALLOGENEIC SMART101 T-LYMPHOID PROGENITOR INJECTION TO ACCELERATE IMMUNE RECONSTITUTION AFTER T-CELL DEPLETED ALLOGENEIC HSCT
por: Jan Boelens, Jaap, et al.
Publicado: (2023)

T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy
por: Garaud, Soizic, et al.
Publicado: (2022)

A DL-4- and TNFα-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors
por: Moirangthem, Ranjita Devi, et al.
Publicado: (2021)

Commentary on the WHO classification of tumors of lymphoid tissues (2008): aggressive B-cell lymphomas
por: Balague Ponz, Olga, et al.
Publicado: (2009)

Commentary on the WHO classification of tumors of lymphoid tissues (2008): indolent B cell lymphomas
por: Ott, German, et al.
Publicado: (2009)

Ticagrelor after Acute Coronary Syndrome: One For All or Part of Personalized Medicine?
por: Akin, Ibrahim, et al.
Publicado: (2022)

Will future microbots be task-specific customized machines or multi-purpose “all in one” vehicles?
por: Wang, Joseph
Publicado: (2021)

Management of infants with congenital diaphragmatic hernia and pulmonary hypertension—one size does not fit all
por: Greenough, Anne
Publicado: (2023)

Limiting the spread of COVID-19 in Africa: one size mitigation strategies do not fit all countries
por: Mehtar, Shaheen, et al.
Publicado: (2020)

A versatile GPCR toolkit to track in vivo neuromodulation: not a one-size-fits-all sensor
por: Labouesse, Marie A., et al.
Publicado: (2021)

Commentary on the WHO classification of tumors of lymphoid tissues (2008): “Gray zone” lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma
por: Hasserjian, Robert P., et al.
Publicado: (2009)

Statins: are they appropriate for all patients?
por: Raal, Frederick J, et al.
Publicado: (2022)

There is only one big risk you should avoid at all costs, and that is the risk of doing nothing
por: Daemen, J.
Publicado: (2015)

Acquired mechanisms of immune escape in cancer following immunotherapy
por: Bryan Iorgulescu, J., et al.
Publicado: (2018)

Bioengineering of bacteria for cancer immunotherapy
por: Nguyen, Dinh-Huy, et al.
Publicado: (2023)

The father of us all
por: Petsko, Gregory A
Publicado: (2002)

Realising the right to health for all people—UHC is the umbrella to deliver health for all
por: Espinosa, Maria Fernanda, et al.
Publicado: (2023)

T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting
por: Hanley, Christopher J., et al.
Publicado: (2020)

Ferroptosis: a new approach for immunotherapy
por: Zeng, Chong, et al.
Publicado: (2020)

Not all pre-registrations are equal
por: Waldron, Sophie, et al.
Publicado: (2022)

Cancer immunotherapy comes of age and looks for maturity
por: Finck, Amanda, et al.
Publicado: (2020)

Immunotherapy in COVID-19: why, who, and when?
por: Sinha, Pratik, et al.
Publicado: (2021)

Two contrasting papers stimulate a commentary on the origins of tumour immunology, current cancer immunotherapies, and the future potential for cancer immunotherapy
por: Bodmer, Walter
Publicado: (2022)

One world, one health, one virology of the mysterious labyrinth of coronaviruses: the canine coronavirus affair
por: Pratelli, Annamaria, et al.
Publicado: (2021)

If there is not one cure for schizophrenia, there may be many
por: Seah, Carina, et al.
Publicado: (2020)

Nothing to do and all day to do it in
por: Petsko, Gregory A
Publicado: (2011)

DISCOVER: much accomplished, but not yet for all
por: Spiegel, Hans M L
Publicado: (2020)

Immunotherapies for COVID-19: lessons learned from sepsis
por: Remy, Kenneth E, et al.
Publicado: (2020)

From macrophage biology to macrophage-based cellular immunotherapies
por: Mass, Elvira, et al.
Publicado: (2021)

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

Potential solutions for manufacture of CAR T cells in cancer immunotherapy
por: Blache, Ulrich, et al.
Publicado: (2022)

Towards evidence-based response criteria for cancer immunotherapy
por: Garralda, Elena, et al.
Publicado: (2023)

Urban design is key to healthy environments for all
por: de Sa, Thiago Herick, et al.
Publicado: (2022)

COVID-19 vaccination and cancer immunotherapy: should they stick together?
por: Brest, Patrick, et al.
Publicado: (2021)

Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era
por: Abid, Muhammad Bilal
Publicado: (2022)

COVID-19 vaccination: returning to WHO's Health For All
por: Torres, Irene, et al.
Publicado: (2020)

Global youth advocating for COVID-19 vaccines for all
por: Kaseje, Neema, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j8g0dkl147nteh5gvndi5qpr8m